KI-Beratung Beta

  • Produktbild: Atlas of Rheumatoid Arthritis
  • Produktbild: Atlas of Rheumatoid Arthritis
- 11%

Atlas of Rheumatoid Arthritis

11% sparen

62,99 € UVP 71,49 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography. The Atlas of Rheumatoid Arthritis will provide clinicians...

Beschreibung

Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography. The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA. Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.

Portrait

Professor Paul Emery is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the LeedsMusculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, UnitedKingdom. Professor Emery was the President of the European League Against Rheumatism(EULAR) from 2009–2011 and has served on the editorial boards major rheumatology journalsincluding Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinicaland Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President ofInternational Extremity MRI Society (ISEMIR) and is a National Institute for Health Research(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award forClinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULARPrize for outstanding contribution to rheumatology research; and the Carol Nachman Prizefor outstanding rheumatology research. Professor Emery’s research interests center around theimmunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connectivetissue diseases. He has a special interest in the factors leading to persistent inflammationand has published over 950 peer-reviewed articles in this area.is the Arthritis Research UK Professor of Rheumatology and Directorofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the LeedsMusculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, UnitedKingdom. Professor Emery was the President of the European League Against Rheumatism(EULAR) from 2009–2011 and has served on the editorial boards major rheumatology journalsincluding Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinicaland Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President ofInternational Extremity MRI Society (ISEMIR) and is a National Institute for Health Research(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award forClinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULARPrize for outstanding contribution to rheumatology research; and the Carol Nachman Prizefor outstanding rheumatology research. Professor Emery’s research interests center around theimmunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connectivetissue diseases. He has a special interest in the factors leading to persistent inflammationand has published over 950 peer-reviewed articles in this area.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

29.06.2015

Abbildungen

XI, 166 illus., 115 illus. in color., farbige Illustrationen, schwarz-weiss Illustrationen

Herausgeber Paul Emery

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

29.06.2015

Abbildungen

XI, 166 illus., 115 illus. in color., farbige Illustrationen, schwarz-weiss Illustrationen

Herausgeber Paul Emery
Verlag Springer Healthcare
Seitenzahl

264

Maße (L/B/H)

21/14,8/1,6 cm

Gewicht

366 g

Auflage

2015

Sprache

Englisch

ISBN

978-1-907673-90-0

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Atlas of Rheumatoid Arthritis
  • Produktbild: Atlas of Rheumatoid Arthritis
  • 1. Classification of rheumatoid arthritis
    2. Pre-rheumatoid arthritis
    What is pre-rheumatoid arthritis?
    Risk factors for rheumatoid arthritis
    Systemic autoimmunity associated with rheumatoid arthritis
    Symptoms without clinical arthritis
    Unclassified arthritis
    3. Early rheumatoid arthritis
    Introduction
    Pathology in early rheumatoid arthritis
    Diagnosis of early rheumatoid arthritis
    Classification of rheumatoid arthritis
    Management of early rheumatoid arthritis
    Recommendations for the management of early rheumatoid arthritis
    4. Established rheumatoid arthritis
    Introduction Stages of established rheumatoid arthritis
    Common clinical presentations

    Introduction Stages of established rheumatoid arthritis
    Common clinical presentations
    5. Remission and rheumatoid arthritis
    Introduction
    Defining remission
    Imaging remission
    Immune-mediated remission
    Drug-free remission
    Optimal dose reduction regimes for patients in remission
    Part TWO Imaging of Rheumatoid Arthritis
    6. Magnetic resonance imaging in rheumatoid arthritis
    Introduction
    Technical aspects
    Visualizing rheumatoid arthritis
    Diagnosing rheumatoid arthritis
    Monitoring disease activity and structural damage
    7. Ultrasound imaging in rheumatoid arthritis

    7. Ultrasound imaging in rheumatoid arthritis Introduction
    Ultrasound and rheumatoid arthritis
    Cartilage damage
    Management of rheumatoid arthritis with ultrasound: diagnosis, therapeutic follow-up, remission, and flare
    Conclusion
    8. Dual energy X-ray absorptiometry in rheumatoid arthritis
    Introduction
    Bone remodeling in rheumatoid arthritis
    Bone damage imaging in rheumatoid arthritis
    Treatment of bone loss in rheumatoid arthritis
    Part three Treatment of rheumatoid arthritis
    9. Methotrexate
    Introduction
    Historical perspective
    Mechanism of action and pharmacokinetics
    Dosing
    Benefits
    Monitoring
    10. Immunotherapy
    Introduction
    Nonbiologic disease-modifying antirheumatic drugs
    Biologic disease-modifying antirheumatic drugs
    Cost-effectiveness of immunotherapy in early rheumatoid arthritis
    Recommendations for the use of disease-modifying antirheumatic drug therapies
    Safety of immunotherapy
    Prospective new targets for immunotherapy
    11. Rituximab
    B-cell development and differentiation
    Efficacy of rituximab in rheumatoid arthritis
    12. Novel therapies in rheumatoid arthritis: small molecules
    Introduction
    Inhibiting intracellular signaling pathways
    Conclusion